Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Krish Patel et al.|Blood|2020Cited by 318
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E. Roeker, Sigrid S. Skånland, Toby A. Eyre et al.|Blood|2021Cited by 70